Johnson & Johnson (JNJ) Valuation
Historical valuation analysis based on 500 data points (2024-08-30 to 2026-08-28)
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divest...
Johnson & Johnson (JNJ) currently trades at a P/E ratio of 30.87 (historical range: 10.14–31.77, median: 25.31), placing it at the 97th percentile — expensive relative to its history, P/S ratio of 6.74 (range: 3.94–6.94, 98th percentile — expensive relative to its history), EV/EBITDA of 113.94 (range: 16.09–117.11, 98th percentile).
Johnson & Johnson appears overvalued relative to its own historical valuation range, trading at elevated multiples across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/E Ratio | 30.87 | 10.14 | 25.31 | 31.77 | 97th | expensive relative to its history |
| P/S Ratio | 6.74 | 3.94 | 4.88 | 6.94 | 98th | expensive relative to its history |
| EV/EBITDA | 113.94 | 16.09 | 27.38 | 117.11 | 98th | expensive relative to its history |
| FCF Yield | 0.00 | 0.00 | 0.02 | 0.06 | 2th | expensive relative to its history |